Biotech News

SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis

Si-Bone (SIBN)Si-Bone2026-09-28 20:09 ESTFDA / regulatory

FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone SANTA CLARA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised

Related news

SIBNSi-Bone2026-02-23 21:09 EST

SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 Guidance

SIBNSi-Bone2026-01-12 14:00 EST

SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025

View all latest news

Si-Bone

Spinopelvic Procedural Solutions SI-BONE is a global medical-device company developing procedural solutions for patients with compromised bone, with a particular focus on the sacropelvic and spinopelvic anatomy. iFuse Technology Platform Its portfolio is built around the iFuse family of implants and instruments. Products include...

Recent company news

SIBNSi-Bone2026-09-28 20:09 EST

SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis

SIBNSi-Bone2026-08-31 20:09 EST

SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026

SIBNSi-Bone2026-08-03 20:09 EST

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance

SIBNSi-Bone2026-07-20 20:09 EST

SI-BONE To Report Second Quarter 2026 Financial Results on August 3, 2026

SIBNSi-Bone2026-06-04 20:09 EST

SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026

Stock data

Close: 18.08 USD
Market cap: 621.33M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States